VEGFA and non-small cell lung carcinoma: Bevacizumab, a humanized monoclonal antibody that targets VEGF, in combination with chemotherapy ± immunotherapy is a treatment option for advanced non-squamous non-small cell lung cancer (NSCLC) patients [3, 4].